Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 7.2%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report)'s share price was down 7.2% on Tuesday . The company traded as low as 1.42 and last traded at 1.42. Approximately 4,018,949 shares changed hands during trading, an increase of 8% from the average daily volume of 3,734,385 shares. The stock had previously closed at 1.53.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CATX. Oppenheimer reissued an "outperform" rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley increased their target price on Perspective Therapeutics from $1.20 to $1.70 and gave the company a "buy" rating in a report on Tuesday, April 9th.

Perspective Therapeutics Price Performance

The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. The stock has a market cap of $856.90 million, a P/E ratio of -14.60 and a beta of 1.56.

Insider Activity

In other Perspective Therapeutics news, insider Markus Puhlmann acquired 280,000 shares of the company's stock in a transaction dated Wednesday, January 24th. The stock was acquired at an average cost of 0.50 per share, with a total value of 140,000.00. Following the purchase, the insider now directly owns 1,375,425 shares in the company, valued at approximately 687,712.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other Perspective Therapeutics news, insider Markus Puhlmann acquired 280,000 shares of the company's stock in a transaction dated Wednesday, January 24th. The stock was acquired at an average cost of 0.50 per share, with a total value of 140,000.00. Following the purchase, the insider now directly owns 1,375,425 shares in the company, valued at approximately 687,712.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company's stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of 0.95 per share, with a total value of 57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The disclosure for this purchase can be found here. In the last three months, insiders purchased 60,758,439 shares of company stock worth $57,576,503. Company insiders own 5.72% of the company's stock.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock valued at $251,000 after purchasing an additional 50,000 shares during the last quarter. Wealth Effects LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $30,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $32,000. Creative Planning acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $35,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $42,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.